The Phase 4 multicenter, observational PaTTerN registry evaluating the use of Inomax (nitric oxide) in newborns with pulmonary hypertension (PH) has enrolled its first patient, Mallinckrodt Pharmaceuticals announced. The registry (NCT03132428) is actively recruiting participants, said the British drug conglomerate. Persistent PH in newborns is a serious, sometimes fatal, condition marked by increased pulmonary vascular pressure.
News
A new study shows that CMR (cardiovascular magnetic resonance) fluoroscopy-guided heart catheterization is a safe method with an appropriate procedure time, high rate of success, and better accuracy than the more commonly used techniques to determine hemodynamic parameters. The study, titled, “CMR fluoroscopy right heart catheterization for cardiac…
Adcirca (tadalafil) showed an acceptable safety profile and effectiveness in a real-world clinical cohort of pediatric patients with pulmonary arterial hypertension (PAH) in Japan. The study, “Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial…
Complexa has obtained $62 million in financing to continue advancing its pulmonary arterial hypertension therapy CXA-10 through the clinical trial process. The company is also developing CXA-10 as a treatment for kidney disease focal segmental glomerulosclerosis, or FSGS. Companies that participated in Complexa’s third round of financing included New Enterprise…
The survival rate of pulmonary hypertension patients who received heart and lung transplants increased after France began giving transplant priority to those experiencing life-threatening episodes, a study reports. The high-priority list covered PH patients who had signed up for heart-lung transplants, or HLTs, and double lung transplants, or  DLTs. Researchers published…
Pulmonary hypertension patients who receive prostacyclin for a long time are at higher risk of developing cardiovascular complications after a lung transplant, a Japanese study reports. The research, published in the International Heart Journal, was titled “High Frequency of Acute Adverse Cardiovascular Events After Lung Transplantation in Patients…
Two pulmonary hypertension treatment groups are now working with a company that helps doctors to streamline the complex process of obtaining insurance company sign-offs on speciality prescriptions, which can take weeks. Arizona Pulmonary Specialists in Phoenix and the pulmonary hypertension unit at Harbor-UCLA Medical Center in Torrance, California, have become clients of  ZappRx. The process…
Obese people with pulmonary arterial hypertension (PAH) are less likely than patients of normal weight to die while hospitalized, finds a study examining the so-called “obesity paradox.” The study, “Relation Between Obesity and Survival in Patients Hospitalized for Pulmonary Arterial Hypertension (from a Nationwide Inpatient Sample Database 2003 to…
The exercise capacity of people with scleroderma who have yet to develop pulmonary arterial hypertension (PAH) diminishes over time, according to an Austrian study. Their lung function during exercise also deteriorates little by little, researchers at the Medical University of Graz reported. The findings raise the question of whether PAH treatment…
New York’s Mount Sinai and Theragene Pharmaceuticals have joined efforts to move a novel investigational aerosol-delivered gene therapy to treat pulmonary hypertension (PH) into a clinical development program. The new therapy, if approved, will be the first to reverse the tissue damage caused by PH. Clinical trials should begin in…
Arena Pharmaceuticals has announced positive results for ralinepag (APD811), an investigational prostacyclin receptor agonist being investigated in a Phase 2 trial to treat pulmonary arterial hypertension (PAH). Ralinepag is an oral drug that targets the prostacyclin pathway. The drug was developed for the treatment of PAH, due to its action on…
Savara’s inhaled sodium nitrite therapy Aironite lowered blood pressure in the upper and lower heart chambers and pulmonary artery of pulmonary hypertension patients, according to an update of a Phase 2 clinical trial. The most improvement occurred in PH patients with a condition known as heart failure with preserved ejection…
